[Effects of salvianolic acid B on expressions of TGF-beta1 and its receptors in liver of rats with dimethylnitrosamine-induced hepatic fibrosis].
OBJECTIVE
To study the therapeutic mechanism of salvianolic acid B (SA-B) in treating hepatic fibrosis.


METHODS
Twenty-four Wistar rats were randomly divided into 3 groups: normal control group, untreated group and SA-B-treated group. Rats in the untreated and SA-B-treated groups were injected intraperitoneally with 0.5% dimethylnitrosamine (DMN) for 4 weeks, daily for 3 days each week at a dose of 10 microg/kg, to induce hepatic fibrosis. Then, rats in the SA-B-treated group were given SA-B orally for another 4 weeks. Hydroxyproline (Hyp) contents in liver tissue of the rats in 3 groups were determined with HCl hydrolysis, and collagen type I, transforming growth factor-beta 1 (TGF-beta1), transforming growth factor-beta receptor type I (TbetaRI) and transforming growth factor-beta receptor type II (TbetaRII) were detected by Western blotting.


RESULTS
The Hyp content and the expressions of collagen type I, TGF-beta1, TbetaRI and TbetaRII in the liver tissue of rats in the untreated group increased significantly as compared with those in the normal control group, while those in SA-B-treated group decreased significantly as compared with those in the untreated group.


CONCLUSIONS
The therapeutic mechanism of SA-B in treating hepatic fibrosis may be related to inhibiting the expressions of TGF-beta1 and its receptors.
Wang
Xiao-Ning
XN
Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Hu
Yi-Yang
YY
Liu
Cheng-Hai
CH
Liu
Ping
P
Zhu
Da-Yuan
DY
D000818:Animals; D001572:Benzofurans / Q000494:pharmacology*; D024042:Collagen Type I / Q000032:analysis; D004128:Dimethylnitrosamine; D006909:Hydroxyproline / Q000032:analysis; D008099:Liver / Q000378:metabolism*; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000378:metabolism*; D008297:Male; D017346:Protein Serine-Threonine Kinases; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000096:biosynthesis* / Q000235:genetics; D016212:Transforming Growth Factor beta / Q000096:biosynthesis* / Q000235:genetics; D053773:Transforming Growth Factor beta1; D053630:Depsides
D001572:Benzofurans; D024042:Collagen Type I; D004128:Dimethylnitrosamine; D006909:Hydroxyproline; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; C508960:TGFB1 protein, human; C508962:Tgfb1 protein, rat; C076944:salvianolic acid B; D053630:Depsides